Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Outpatient Radioablation Therapy for Thyroid Cancer Patients with Minimal Radiation Exposure to the Family Members

갑상선암 환자의 방사선옥소 외래치료시 가족 구성원의 방사선량 측정

  • Park, Hee-Myung (Myongji Hospital, School of Medicine, Kwandong University) ;
  • Jang, Jung-Woong (Myongji Hospital, School of Medicine, Kwandong University) ;
  • Yang, Hee-Chul (Myongji Hospital, School of Medicine, Kwandong University) ;
  • Kim, Young-Gook (Myongji Hospital, School of Medicine, Kwandong University)
  • 박희명 (관동대학교 의과대학 명지병원 핵의학과) ;
  • 장정웅 (관동대학교 의과대학 명지병원 핵의학과) ;
  • 양희철 (관동대학교 의과대학 명지병원 핵의학과) ;
  • 김영국 (관동대학교 의과대학 명지병원 핵의학과)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Postoperative thyroid remnant radioablation therapy is necessary to reduce the recurrence and mortality rates as well as to prepare the patients for a proper long term surveillance of well-differentiated thyroid cancers. The radiation safety rules of the government require the patient to be isolated in a hospital if the expected radiation exposure to the family members would be greater than 5 mSv (500 mRem). The purpose was to measure the radiation received by the family members of patients who received large doses of NaI-131. Material and Methods: We have administered 12 therapy doses ranging from 3.70-5.55 GBq (100 to 150 mCi) to 11 patients, and released them immediately if they met the radiation safety criteria. Informed consent was obtained from the subjects prior to the therapy, and each of them agreed to follow written radiation safety instructions. TLD badges were used to measure the radiation dose received by the family members and the room adjacent to the patient's bed room during the first 72 hours. Results: The average dose received by the family members who spent the most time in the closest distance with the patients was 0.04 mSv with a range of 0.01-0.17 mSv. Even the highest dose was only about 3% of the limit set by the government. The average radiation dose to the outer wall of the patient's room was 0.15 mSv. Conclusion: It is concluded that I-131 ablation therapy can be administered to outpatients safely to thyroid cancer patients who meet the established radiation safety criteria and follow the instructions.

목적: 이 연구에서는 갑상선 암 수술 후 방사선요오드-131 치료를 받은 환자가 방사선 안전 퇴원 기준에 따라 즉시 퇴원 했을 때 환자의 가족이 받는 방사선량을 측정하여 정부의 허용범위와 비교하고자 하였다. 대상 및 방법: 의사가 설명한 방사선 안전지침을 이해하고 그대로 준수하기로 동의한 11명의 외래 환자에게 3.70 - 5.55 GBq의 NaI-131을 투여하고 가족과 환자가 생활하는 방 주변의 방사선량을 측정하였다. 결과: 환자의 가족이 받은 최대 방사선량은 정부의 허용범위 보다 훨씬 적은(5% 이내) 것으로 나타났다. 결론: 본 연구자들은 외래환자 I-131 치료가 안전하다는 것을 확인하였다. 따라서 외래환자 I-131 치료를 통해 격리 시설부족으로 인한 치료지연을 줄일 수 있고, 앞으로 갑상선 암환자 치료 관리에 도움을 줄 수 있을 것으로 확신한다. 또한 환자와 정부의 의료비용 절감 효과도 기대된다.

Keywords

References

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28 https://doi.org/10.1016/0002-9343(94)90321-2
  2. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003;113:2102-07 https://doi.org/10.1097/00005537-200312000-00008
  3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24 https://doi.org/10.1210/jcem-71-2-414
  4. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnson DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-20 https://doi.org/10.1210/jc.75.3.714
  5. Thyroid Carcinoma. Version 1. 2003. Clinical Practice Guidelines in Oncology - National Comprehensive Cancer Network, 2003
  6. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 hyperthyroid therapy. J Nucl Med. 1991;32:169-73
  7. Department of science and technology, Korea: Announcement No.2005-35, section 12. Isolation of patients. 과학기술부 고시 제 2005-35-제12조 환자격리. Available at 한국 원자력 안전기술원. Available from: URL: http://www.kins.re.kr /원자력관계법령/ 과학 기술부고시/방사선 010/46조/12조
  8. Questionnairs for occupancy factor (Table 1) and contamination factor (Table 2), and maximum Permissible I-131 Dose (Table 3): Developed and calculated using the NRC guide 8.39 by the Radiation Safety Office, Indiana University, Indianapolis, Indiana
  9. U.S. Nuclear Regulatory Commission's Regulatory Guide 8.39 Release of patients administered radioactive materials. April 1997. Available from: URL: http://www.nrc.gov/electronic reading room/ regulatory guides/regulatory guides (by division)/occupational health (8)/8.39 ML003739575
  10. Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine therapy for thyroid carcinoma. JAMA 2000;283:2272-4 https://doi.org/10.1001/jama.283.17.2272
  11. Venencia CD, Germanier AG, Bustos SR, Giovannini AA, Wyse EP. Hospital discharge of patients with thyroid carcinoma treated with I-131. J Nucl Med 2005;43:61-5
  12. Pacini F, Ladenson PW, Schlumberger M, Driedger A, et al. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. J Clin Endocrinol Metab 2005;91:926-32 https://doi.org/10.1210/jc.2005-1651
  13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2006;16:109-42 https://doi.org/10.1089/thy.2006.16.109
  14. Department of science and technology, Korea: Announcement No.2005-35, sections 13 and 46: Discharging patient excreta from medical facility. 과학기술부 고시 제 2005-35, 46조, 13조 (의료기 관의 진료환자 배설물). Available at 한국 원자력 안전기술원. Available from: URL:http://www.kins.re.kr/원자력관계법령/과학기 술부고시/방사선 010/46조/13조
  15. Bourguignon MH. The potential impact of radiation biology in radiation protection in nuclear medicine and corresponding regulatory issues. Proceedings of the 9th congress of world federation of nuclear medicine and biology, Seoul, Korea. 22-27 Oct., 2006. World J Nucl Med 2006;5:362-64
  16. Sanders CL, Sohn S. Evidence for radiation hormesis from epidemiological studies of cancer. Proceedings of the 9th congress of world federation of nuclear medicine and biology, Seoul, Korea. 22-27 Oct., 2006. World J Nucl Med 2006;5:258-60
  17. Hickey RJ, Bowers EJ, Spence DE, Zemel BS, Clelland AB, Clelland RC. Low level ionizing radiation and human mortality: Multi-regional epidemiological studies. Health Phys 1981;40:625-41 https://doi.org/10.1097/00004032-198105000-00003